New model “Serial CTRS” shows promise in predicting survival for advanced NSCLC patients
San Diego, CA — April 25, 2025 — At the annual meeting of the American Association for Cancer Research (AACR 2025), health tech startup Onc.AI made waves with the debut of its new AI model, Serial CTRS, developed to more accurately forecast overall survival outcomes in patients with advanced non-small cell lung cancer (NSCLC).
The Serial CTRS model uses advanced machine learning to interpret medical imaging and clinical data over time, giving doctors a continuously evolving picture of a patient’s prognosis. Rather than relying solely on fixed scan intervals or standard response metrics like RECIST 1.1, the model introduces a dynamic scoring system based on radiomic patterns and longitudinal clinical input.
“This tool is about giving oncologists sharper, earlier insights,” said Dr. Elena Rossi, Chief Medical Officer at Onc.AI. “Serial CTRS reflects the patient’s journey—not just snapshots of it.”
🔎 Study Results Shared at AACR Conference
During a featured poster session, Onc.AI presented results from a large, multi-institutional study evaluating the AI model. Findings indicated that Serial CTRS:
- Outperformed traditional methods in predicting overall survival.
- Detected non-response to therapy weeks earlier than standard metrics.
- Provided a more individualized forecast by analyzing data from multiple time points.
You can access the official AACR 2025 presentation and poster here:
🔗 https://www.aacr.org/meeting/aacr-annual-meeting-2025
💡 How It Works
Serial CTRS functions by extracting features from routine CT scans and combining them with relevant clinical data. Its deep learning engine tracks tumor response patterns over time, updating the prognosis as new data becomes available. This could help oncologists adjust treatments earlier, potentially improving both survival and quality of life.
“It’s like giving physicians a real-time dashboard instead of a static report,” explained Dr. James Lin, Director of Data Science at Onc.AI. “That can make all the difference when time is critical.”
📣 Experts React to the Announcement
The oncology community has responded positively to the announcement. Dr. Lisa Campbell, a thoracic oncologist at the Dana-Farber Cancer Institute, commented, “There’s real clinical value in moving beyond point-in-time assessments. This kind of AI could change how we monitor and adapt treatments in aggressive cancers like NSCLC.”
🏢 About Onc.AI
Onc.AI is a health technology company building intelligent tools for oncology care. By harnessing artificial intelligence, the company aims to improve cancer treatment through deeper data interpretation, decision support, and predictive analytics.
Learn more about the company’s innovations at:
🌐 https://www.onc.ai